The COMBAT project uses AI, advanced genomics, and organ-on-chip technology to understand why dengue becomes severe in some patients, with India leading genomics research. Two dengue vaccines are advancing: Takeda's Qdenga received Indian regulatory approval with 84.1% efficacy, while ICMR's DengiAll is in Phase III trials across 20 sites.
The Indian Express
· Apr 29, 2026
· health
· 3 min de lectura
High
Verificación: Verificado
Global science race accelerates to crack dengue's deadly code
Dengue incidence has increased dramatically from 505,000 cases in 2000 to 14.6 million in 2024, with projections suggesting further 60% increase by mid-century.
◉
Health & Medicine
8293 artículos relacionados
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% coincidencia
Alzheimer's Drug Approvals Split Regulators on Benefits vs. Safety Tra…
News-Medical · 99% coincidencia
Cancer vaccine shows striking tumor elimination in international trial
Malay Mail · 99% coincidencia
WHO prioritizes three therapeutics and two vaccine candidates for Bund…
World Health Organization (WHO) · 99% coincidencia
Spanish health chief resigns after admitting he jumped vaccine queue
Reuters · 99% coincidencia
Cobertura Relacionada
7NEWS · Aug 23
Model's Foot Cut Led to Heart Surgery, Baby Loss—Now Advocating for Better Diagnostics
Australian model Leah Ramsey lost her baby after a small foot cut triggered a rare heart infection that was repeatedly m…
Informanté · Aug 23 South Africa Shares FMD Vaccines as Region Strengthens Disease ControlsSouth Africa reports its largest-ever FMD outbreak is coming under control through accelerated vaccination and regional …
Al Jazeera · Aug 23 Solar telemedicine kiosks expand healthcare access across rural ChadSolar-powered telemedicine kiosks in rural Chad enable remote doctor consultations at a fraction of traditional travel c…
Inquirer.net · Aug 23 Prince Harry returns to UK amid family rifts, seeking reconciliation with monarchyPrince Harry and Meghan Markle are relocating back to Britain after six years in California, potentially signaling recon…
Sesgo y Encuadre
⚖
Article presents international dengue research efforts with positive framing of India's scientific contributions, using optimistic language about technological advances without significant critical perspective.
Bias Direction
center-left
Confidence
MED
Progress narrative emphasizing scientific advancement and international collaboration, with India positioned as a capable research partner. Uses aspirational language ('leap forward,' 'accelerates') to frame research efforts positively.
deadly code
crack dengue's deadly code
accelerates
leap forward
surged
growing risk
Cost-effectiveness and accessibility of new technologies for developing nations
Challenges in implementing findings in resource-limited settings
Ethical concerns regarding organ-on-chip and AI research applications
Voices of dengue patients or affected communities
Criticism or skepticism about timeline feasibility
Perspectives from competing research programs or alternative approaches
Public health infrastructure gaps that may hinder implementation
Impacto Geopolítico
🌎
International dengue research initiative led by EU and India accelerates vaccine development and genomics research, positioning India as a key biotech hub while addressing a rapidly expanding global health threat.
Escalation Risk
low
Confidence
HIGH
India
European Union
Sweden
Southeast Asia
Global (endemic and non-endemic regions)
India strengthens its position as a biomedical research powerhouse through EU collaboration, gaining access to advanced technologies and funding while establishing itself as essential to global health security. EU leverages Indian genomics expertise and clinical infrastructure. This represents a shift toward multipolar health governance with emerging economies as equal research partners rather than passive recipients.
Similar to the polio eradication initiative (1988-present) where international collaboration combined developed-nation funding with developing-nation field expertise and population access, creating sustainable global health infrastructure.
Lente Económico
📈
International dengue research initiatives with India's significant genomics contribution are accelerating vaccine development and public health infrastructure, addressing a disease surge from 505K to 14.6M cases globally.
Market Signal
bullish
Confidence
HIGH
Biotechnology and pharmaceutical manufacturing
Healthcare and medical devices
Public health infrastructure
Research and development
Medical tourism and diagnostics
Consumers benefit from accelerated vaccine development reducing dengue infection risks, improved diagnostic capabilities, and strengthened public health surveillance. Healthcare costs may decrease long-term through prevention, though short-term vaccine pricing and healthcare spending may increase.
Governments likely to increase biotech R&D funding, strengthen disease surveillance infrastructure, expedite vaccine approval processes, and potentially mandate dengue vaccination in endemic regions. International collaboration frameworks may expand for pandemic preparedness. India's biotech sector may receive policy support for technology transfer and manufacturing capacity.